*Update as of January 2017:
AUVI-Q (known as Allerject in Canada) is returning to the U.S. on February 14th, 2017
They also announced the list price for insurance companies is $4,500 for a two-pack of the devices with a trainer (approximately 7x the list price for Mylan’s branded EpiPen two pack). However, consumers will not pay that price with their AUVI-Q AffordAbility access program, noted as follows:
- Americans with commercial insurance, including those with high-deductible plans, will be able to obtain AUVI-Q for $0 out-of-pocket.
- AUVI-Q will be available free of charge to American patients with a household income of less than $100,000 who do not have government or commercial insurance.
- The cash price for AUVI-Q is $360 for a two-pack of the devices, and will be available to those patients without government or commercial insurance.
There is no news yet on if and when the product will launch in Canada. Read Kaleo’s press release to learn more about their U.S. launch. You can also read two articles that go into further detail about their pricing: Allergic Living and CNBC (which also has a video clip).
Original blog post below:
On October 26, 2016, it was announced that Auvi-Q®, known as Allerject in Canada, is relaunching in the U.S. during the first half of 2017 by Kaléo – the pharmaceutical company that originally created this device.
Auvi-Q devices were voluntarily recalled in 2015 due to the possibility of incorrect dosage delivery, Allerject was also recalled at the same time in Canada. Sanofi, who owned the rights to the devices at that time, later returned all rights back to Kaléo.
Right now, Kaléo is focused on relaunching in the U.S. and are evaluating alternatives for bringing it back to international markets. We have reached out to the Kaléo team to discuss this further.
Be sure to sign-up for our emails to receive important updates, including more details about this relaunch.
In the meantime, we invite you to read the press release from Kaléo and also Allergic Living’s interview with Kaléo senior management on the relaunch, what will be done to ensure the devices are reliable, and other important details about the device.